داروسازی کنسرت: افکار دارویی در حال رفتن به سال 2018

Summary

Shares have risen by over 160% since I stated the company was set for a transformational 2017.

The deal with Vertex provided much-needed credibility as well as strengthened the balance sheet to extend the operational runway into 2021.

The U.S. Patent and Trademark Office’s decision to deny Incyte’s petition was a significant positive.

Results from the phase 2a study evaluating CTP-543 in alopecia areata in the first quarter of 2018 and the first pivotal readout evaluating AVP-786 as a first-in-class treatment for agitation in Alzheimer’s disease (Q3) are two important catalysts.

Readers who have done their due diligence should purchase a pilot position in the near term. I suggest waiting for dips over the next quarter or two to add to your stakes selectively.

Shares of Concert Pharmaceuticals (CNCE) have risen by over 160% since my January article in which I stated the company was “set for a transformational 2017.”

My original thesis was based on the value likely to be created via their deuterated platform of drug candidates progressing in the clinic, namely CTP-543 in alopecia areata and their deuterated version of Vertex Pharmaceuticals’ (VRTX) ivacaftor CTP-656. For the former, I noted that alopecia areata affects up to 650,000 Americans and there are no FDA approved treatments for the indication. For the latter, I pointed out that ivacaftor generated $632 million in 2016 revenue for Vertex and top-line results for a phase 2 study could come by the end of the year. I was especially excited here as there was also an open label ivacaftor comparator arm included and it’s not often that a small biotech concern has a drug candidate that worries the management team of a large biotech firm. After all, we discussed how if approved CTP-656 would be a more convenient alternative to ivacaftor (Kalydeco) as it allows for once-daily dosing and doesn’t require the patient to take it with fat containing food.

Reference

عضویت در کانال زیست فن☑

داروسازی کنسرت: افکار دارویی در حال رفتن به سال ۲۰۱۸ – اخبار زیست فناوری

Rate this post
برچسب‌ها
نمایش بیشتر

نوشته‌های مشابه

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *

دکمه بازگشت به بالا
EnglishIran
بستن
بستن